AbbVie (ABBV) continued gains for seven straight sessions of gains, as the stock closed higher Friday. The North ...

AbbVie has also submitted an application to the FDA, seeking the label expansion for Skyrizi to include the UC indication in the United States. The regulatory filing is yet to be accepted for review.

AbbVie ABBV stock has declined 12.6% in the past three months. The stock is also trading below its 50-day and 200-day moving ...

Physicians have delivered a boost to AbbVie’s hopes of turning Skyrizi into a $17-billion-a-year drug. The 101 gastroenterologists polled by Spherix Global Insights talked up Skyrizi’s promise ...

The regulatory nod goes to risankizumab, a drug that North Chicago, Illinois-based AbbVie already sells under the name “Skyrizi” for approved uses in plaque psoriasis and psoriatic arthritis.

One of the up-and-coming drugs AbbVie is pinning its hopes on to make up for falling Humira sales, Skyrizi, just beat out its competitor Stelara, from Johnson & Johnson on many points in a Phase 3 ...

Offsetting Humira's expected declines, AbbVie looks well-positioned with next-generation immunology drugs. In particular, recently launched drugs Skyrizi and Rinvoq have shown improved efficacy ...

AbbVie continued to benefit from strong sales growth for Rinvoq and Skyrizi. The company’s outlook was also better than the estimates, faring well for its stock. Separately, see What’s Next ...

Advertisement Apart from the above indications, AbbVie is currently evaluating Skyrizi in a phase III study for ulcerative colitis. AbbVie is developing Skyrizi in collaboration with Boehringer ...

Improved sales expectations for Skyrizi and Rinvoq and acquisitions in oncology and neuroscience add confidence AbbVie can continue growing. I now see EPS growing at 8.2% per year through 2030 ...